{"product_id":"achl-vrio-analysis","title":"Achilles Therapeutics plc (ACHL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Achilles Therapeutics plc (ACHL) truly built for lasting success? This razor-sharp VRIO analysis distills whether their key assets offer a sustainable competitive advantage - or if they're just keeping pace. Dive in below to see the definitive verdict on their market power.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 1. PELEUS™ Bioinformatics Platform\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core intellectual property of Achilles Therapeutics plc, the PELEUS™ Bioinformatics Platform, right as the company was winding down its operations. This platform was their engine for finding the best cancer targets, but its value is now purely historical given the company’s strategic pivot. Here’s the quick math on what it was worth and why it was hard to copy.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Core Engine for Target Identification\u003c\/h3\u003e\n\u003cp\u003eThe PELEUS™ platform provided the essential computational backbone for Achilles Therapeutics to move from raw tumor sequencing data to actionable drug targets. It uses sophisticated Bayesian statistical algorithms to sift through mutations and pinpoint clonal neoantigens - the protein markers present on all cancer cells but not on healthy ones. This capability was directly applied to their lead programs in advanced non-small cell lung cancer (NSCLC) and metastatic melanoma. The platform was trained and validated using data from \u003cstrong\u003eover 10,000 neoantigens\u003c\/strong\u003e, giving it a deep, proprietary knowledge base for predicting which targets would actually generate a potent T cell response. That’s precision oncology at the data level.\u003c\/p\u003e\n\n\u003ch3\u003eRarity and Imitability: Proprietary Depth\u003c\/h3\u003e\n\u003cp\u003eHonestly, the rarity stemmed from the specific combination of its AI\/ML application and the data it was trained on. Competitors using public data, like that from the Immune Epitope Database (IEDB), simply couldn't match its performance. The platform demonstrated superior ranking performance compared to state-of-the-art methods, which is a huge deal in drug discovery. Imitability was high because it wasn't just an algorithm; it was years of proprietary data integration, including exclusive access to the TRACERx study knowhow and genomics data. It would take a competitor significant time and capital to replicate that data fidelity. Still, the platform’s assets, including the TRACERx license and associated data, were transferred to AstraZeneca for a cash consideration of \u003cstrong\u003e$12,000,000\u003c\/strong\u003e in late 2024, showing its tangible, albeit non-exploitable, value.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: The Liquidation Reality\u003c\/h3\u003e\n\u003cp\u003eThis is where the analysis hits a wall. For a resource to provide a sustained competitive advantage, the organization must be structured to exploit it. While PELEUS was central to the entire strategy, Achilles Therapeutics plc commenced a members’ voluntary liquidation on \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e, following shareholder approval. This organizational collapse means the capability to use the platform - whether for internal development or external licensing - is effectively zero now. If onboarding takes 14+ days, churn risk rises, but here, the entire company structure dissolved. The competitive advantage, which was previously sustained, became temporary the moment the liquidation process began.\u003c\/p\u003e\n\n\u003cp\u003eHere is the quick summary of the VRIO assessment for the platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore\/Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eIdentifies highly potent, patient-specific clonal neoantigens.\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eProprietary AI\/ML trained on unique, large-scale proprietary data sets (TRACERx).\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh barrier due to years of proprietary data integration and algorithm refinement.\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eOrganization entered voluntary liquidation in March 2025; no structure to exploit the asset.\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage (due to O=No)\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe key takeaways for any remaining stakeholders revolve around the disposition of the technology. You should review the specifics of the \u003cstrong\u003e$12,000,000\u003c\/strong\u003e asset sale to AstraZeneca to understand the residual value realization. The platform's technical superiority is not in question, but its strategic utility ended with the company’s dissolution.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlatform trained on \u003cstrong\u003eover 10,000\u003c\/strong\u003e neoantigens.\u003c\/li\u003e\n\u003cli\u003eAsset transfer value: \u003cstrong\u003e$12,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLiquidation date: \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCore function: Clonal neoantigen selection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 2. Clonal Neoantigen Targeting Intellectual Property\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This forms the basis of their therapeutic approach, offering a path to personalized medicine for solid tumors, which is a massive market need.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While neoantigen targeting is a field, their specific, validated set of targets and associated IP is unique to them.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate to High. Competitors can pursue similar targets, but the specific patent estate is hard to copy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP is an asset being managed by the liquidators; its value is now in potential sale or licensing. The Joint Liquidators were appointed on March 20, 2025. The expected capital return to ordinary shareholders is approximately $1.50 to $1.66 per share.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The value is tied to the IP's transferability during the wind-down process. The TRACERx license and materials were transferred to AstraZeneca for $12 million.\u003c\/p\u003e\n\n\u003cp\u003eThe intellectual property is underpinned by platform validation and clinical output:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe PELEUS™ bioinformatics platform is patented.\u003c\/li\u003e\n\u003cli\u003eThe platform was built and validated using data from the TRACERx study, which enrolled 815 patients with NSCLC.\u003c\/li\u003e\n\u003cli\u003eOver 10,000 predicted clonal neoantigens have been validated with human patient data.\u003c\/li\u003e\n\u003cli\u003eAs of August 2024, the company had delivered 5 products containing more than 1 billion cNeT.\u003c\/li\u003e\n\u003cli\u003eThe median cNeT dose for the last 18 patients in an update was 172 million cNeT, an increase from the 18 million cNeT median in the December 2022 update.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Asset\/Metric\u003c\/td\u003e\n\u003ctd\u003eAssociated Value\/Volume\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRACERx License Sale Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrior to Liquidation Proposal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$95.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidated Clonal Neoantigens\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;10,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlatform Validation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNegative EBITDA (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$67.23 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrior to February 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Capital Return per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.50 to $1.66\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProposed Liquidation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 3. Personalized T-Cell Therapy (cNeT) Approach\n\u003c\/h2\u003e\n\n\u003cp\u003e\nThe following analysis is based on the clonal neoantigen targeting T-cell (cNeT) therapy approach, which utilized the proprietary PELEUS™ bioinformatics platform for personalized T-cell product development.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePresent (Demonstrated clinical activity and engraftment potential)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate (Specific cNeT refinement is distinct)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh (Replication requires multi-year, capital-intensive clinical and manufacturing setup)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eImpaired (Operational execution paused)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary (Knowledge retained, execution capability dormant)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue Metrics:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial data from the CHIRON and THETIS trials showed stable disease in \u003cstrong\u003e4 out of 6\u003c\/strong\u003e patients following the first disease evaluation by scan six weeks post-infusion.\u003c\/li\u003e\n\u003cli\u003eEvidence of cNeT engraftment was observed in \u003cstrong\u003e2 out of 4\u003c\/strong\u003e patients assessed in early cohorts.\u003c\/li\u003e\n\u003cli\u003eIn one patient case study (THETIS trial, Patient T-05), up to \u003cstrong\u003e53%\u003c\/strong\u003e of the manufactured T cells were reactive to the patient's own clonal neoantigens following stimulation.\u003c\/li\u003e\n\u003cli\u003eThe VELOS™ Process 2 manufacturing showed an \u003cstrong\u003e18-fold\u003c\/strong\u003e increase in median cNeT generated compared to Process 1 in a proof-of-concept study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability and Organization Metrics:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase I\/IIa CHIRON and THETIS clinical trials were officially closed in \u003cstrong\u003eSeptember 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePlanned peak annual manufacturing capacity across UK (Catapult) and US (CBM) sites was up to \u003cstrong\u003e600 doses\u003c\/strong\u003e combined to support the trials.\u003c\/li\u003e\n\u003cli\u003eThe UK facility (Catapult) was GMP certified to produce clinical grade doses with an initial peak annual capacity of \u003cstrong\u003e200 cNeT doses\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe US facility (CBM) was planned for an initial annual capacity of \u003cstrong\u003e150-200 doses\u003c\/strong\u003e at peak production.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents were reported as \u003cstrong\u003e$95.1 million\u003c\/strong\u003e as of \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) expenses for the second quarter ended June 30, 2024, were \u003cstrong\u003e$13.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket capitalization was reported as \u003cstrong\u003e$29.17 million\u003c\/strong\u003e as of September 19, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 4. TRACERx Study Data License and Know-How\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Access to the TRACERx bioinformatic pipeline, patient sequencing, and medical data provides a rich, foundational dataset for their platform.\u003c\/p\u003e\n\u003cp\u003eThe value is underpinned by the scale and depth of the data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe TRACERx study is one of the largest tumor evolution studies, generating deep sequencing multi-region and multi-time-point genetic data.\u003c\/li\u003e\n\u003cli\u003eThe dataset includes data from over \u003cstrong\u003e3,200\u003c\/strong\u003e tumor samples from over \u003cstrong\u003e800\u003c\/strong\u003e lung cancer patients.\u003c\/li\u003e\n\u003cli\u003eThe TRACERx Lung study had a target accrual of \u003cstrong\u003e842\u003c\/strong\u003e patients from \u003cstrong\u003e14\u003c\/strong\u003e hospital sites across the United Kingdom.\u003c\/li\u003e\n\u003cli\u003eData collection was complete for the first \u003cstrong\u003e421\u003c\/strong\u003e patients in the TRACERx Lung study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis data is integrated with the proprietary AI-Powered PELEUS™ bioinformatics platform to identify clonal neoantigens.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTRACERx Data Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Tumor Samples (Deep Sequencing)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e3,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patients (Target Accrual)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e800\u003c\/strong\u003e \/ \u003cstrong\u003e842\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital Sites (TRACERx Lung)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRACERx Lung Data Collection Complete (Patients)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e421\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Expenses Related to CRT License (3M Ended 3\/31\/22)\u003c\/td\u003e\n\u003ctd\u003eLess than \u003cstrong\u003e$0.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This specific, deep dataset from a major study is not available to others.\u003c\/p\u003e\n\u003cp\u003eThe license granted an \u003cstrong\u003eexclusive\u003c\/strong\u003e, sublicensable license to the TRACERx patents and bioinformatic data for use in neoantigen cell therapies and diagnostics. TRACERx represents the largest investment in lung cancer research by Cancer Research UK.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very High. It is a contractual asset tied to Cancer Research Technology Limited (CRT); it cannot be recreated.\u003c\/p\u003e\n\u003cp\u003eThe asset was secured via a License Agreement with CRT, granting access to intellectual property and know-how. Achilles exercised an option to acquire the TRACERx patents with \u003cstrong\u003eno consideration\u003c\/strong\u003e upon IPO, though final acquisition was not finalized as of mid-2023.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLicense covers: (i) therapeutic field of neoantigen cell therapies and adoptive cell transfer; and (ii) the neoantigen diagnostic field.\u003c\/li\u003e\n\u003cli\u003eExpenses related to the CRT License Agreement for the six months ended June 30, 2023, and 2022, were less than \u003cstrong\u003e$0.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The license terms dictate how this data can be transferred or utilized by a successor entity.\u003c\/p\u003e\n\u003cp\u003eThe organization structure around this asset was defined by the initial license terms with CRT and the subsequent strategic review culminating in an asset transfer.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe transfer of the commercial license of data and samples to AstraZeneca was agreed upon for a total payment of \u003cstrong\u003e$12 million\u003c\/strong\u003e in December 2024.\u003c\/li\u003e\n\u003cli\u003eThe transaction concluded Achilles' strategic review initiated in September 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. As long as the license terms were favorable for transfer, this data access was a long-term asset.\u003c\/p\u003e\n\u003cp\u003eThe scientific value recognized by AstraZeneca, leading to the \u003cstrong\u003e$12 million\u003c\/strong\u003e transfer, confirms the sustained, high value of the proprietary data asset derived from the TRACERx study.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 5. Strategic Collaboration Assets (e.g., Arcturus Therapeutics)\n\u003c\/h2\u003e\n\u003cp\u003eThe strategic collaboration asset involves the research agreement with Arcturus Therapeutics, announced on May 22, 2024, focusing on second-generation personalized mRNA cancer vaccines.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eAssociated Financial\/Statistical Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Partner\u003c\/td\u003e\n\u003ctd\u003eArcturus Therapeutics Holdings Inc.\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Focus\u003c\/td\u003e\n\u003ctd\u003eSecond-generation personalized mRNA cancer vaccines (sa-mRNA PCVs)\u003c\/td\u003e\n\u003ctd\u003eCombines Achilles' PELEUS technology with Arcturus' STARR® platform.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAchilles Cash Position (Q2 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$95.1 million\u003c\/strong\u003e (as of June 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eExpected to support operations through 2025, including the Arcturus collaboration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Asset Sale Value\u003c\/td\u003e\n\u003ctd\u003eTechnology Assets (TRACERx and MAP data\/samples) to AstraZeneca\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12M\u003c\/strong\u003e total payment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidation Capital Return Estimate\u003c\/td\u003e\n\u003ctd\u003ePer ordinary share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e£1.20 to £1.32\u003c\/strong\u003e or \u003cstrong\u003e$1.50 to $1.66\u003c\/strong\u003e per share.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The research collaboration with Arcturus Therapeutics on second-generation mRNA cancer vaccines shows the platform's potential use in other modalities, leveraging the PELEUS platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The specific agreement terms and the initial joint insights gained from combining the PELEUS and STARR® platforms are unique at the time of formation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The underlying technology concepts are imitable, but the specific joint findings and the established partnership structure are not immediately replicable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The status of this collaboration post-liquidation is key; its value is in what can be sold off or transferred, as the company commenced members' voluntary liquidation on March 20, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Its value depends on the terms of the collaboration agreement upon asset sale or the realization of any residual value during the winding up process, following the company's delisting from Nasdaq on March 20, 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe collaboration aimed to generate pre-clinical IND-enabling data.\u003c\/li\u003e\n\u003cli\u003eAchilles' market capitalization was reported as \u003cstrong\u003e$56.7 million\u003c\/strong\u003e around February 28, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company's current ratio was reported as \u003cstrong\u003e6.04\u003c\/strong\u003e prior to liquidation filing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 6. Clinical Trial Experience and Interim Data\n\u003c\/h2\u003e\n\u003cp\u003e\nThe interim Phase I\/IIa data, especially from the Enhanced Host Conditioning (EHC) cohort, provides crucial proof-of-concept signals for durability.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eCHIRON (NSCLC)\u003c\/th\u003e\n\u003cth\u003eTHETIS (Melanoma)\u003c\/th\u003e\n\u003cth\u003eCombined Cohort (All)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Dosed (Total Since Dec 2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Receiving EHC (Cohort C)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian cNeT Dose Achieved\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\n\u003cstrong\u003e172 million\u003c\/strong\u003e (vs. 18 million in Dec 2022 update)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e172 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProducts Dosed Over 100M cNeT\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProducts Dosed Over 1 Billion cNeT\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStable Disease\/Tumor Reduction (Higher Dose)\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e\n\u003cstrong\u003e3 of 12\u003c\/strong\u003e (\u003cstrong\u003e25%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3 of 12\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe company reported a strong cash position supporting operations through \u003cstrong\u003e2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of March 31, 2024: \u003cstrong\u003e$112.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of June 30, 2024: \u003cstrong\u003e$95.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2024: \u003cstrong\u003e$86.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdditional R\u0026amp;D tax credit received in October 2024: \u003cstrong\u003e$12.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2024: \u003cstrong\u003e$19.6 million\u003c\/strong\u003e ($\u003cstrong\u003e0.48\u003c\/strong\u003e per share).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nData showing persistence in solid tumors, particularly in checkpoint refractory patients, is valuable.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAll trial participants were late-stage, checkpoint refractory patients with progressive disease at the time of lymphodepletion.\u003c\/li\u003e\n\u003cli\u003eThe EHC cohort was designed to evaluate cNeT engraftment and persistence beyond \u003cstrong\u003e28 days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe proprietary PELEUS™ bioinformatics platform is used to identify clonal neoantigens.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nYou can’t easily replicate the specific patient cohort outcomes or the learning curve from running those trials.\n\u003c\/p\u003e\n\u003cp\u003e\nThe technology platform has roots in the TRACERx study, which generated deep sequencing multi-region and multi-time point genetic data from over \u003cstrong\u003e3,200\u003c\/strong\u003e tumor samples from nearly \u003cstrong\u003e800\u003c\/strong\u003e lung cancer patients.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe data package is a tangible asset that can be sold to a larger pharma partner looking to acquire a clinical asset.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CHIRON and THETIS Phase I\/IIa clinical trials were closed as of September 2024.\u003c\/li\u003e\n\u003cli\u003eThe company engaged BofA Securities to explore and review value-maximizing strategies.\u003c\/li\u003e\n\u003cli\u003eTechnology assets were previously transferred from the TRACERx NSCLC Study to AstraZeneca for \u003cstrong\u003e$12 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nTemporary. The data's value decays as newer data emerges elsewhere, but it's a key asset now.\n\u003c\/p\u003e\n\u003cp\u003e\nResearch and development (R\u0026amp;D) expenses for Q1 ended March 31, 2024, were \u003cstrong\u003e$10.1 million\u003c\/strong\u003e. R\u0026amp;D expenses for Q3 2024 were \u003cstrong\u003e$16.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$14.7 million\u003c\/strong\u003e year-over-year.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 7. Internal Manufacturing Infrastructure (Pre-Closure)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Having built out internal manufacturing capabilities meant better control over the complex, personalized T-cell product supply chain.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Specialized cell therapy manufacturing capacity is scarce.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building GMP-compliant facilities takes significant time and capital investment. The Cell \u0026amp; Gene Therapy Catapult manufacturing centre in Stevenage, UK, was backed by over \u003cstrong\u003e£75m\u003c\/strong\u003e of funding.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This infrastructure is likely being mothballed or sold; its value is in its physical existence and regulatory compliance status. The Company announced the closure of its Phase I\/IIa CHIRON and THETIS clinical trials in September 2024, following discontinuation of the TIL-based cNeT program. As of June 30, 2024, the Company had cash and cash equivalents of \u003cstrong\u003e$95.1 million\u003c\/strong\u003e, expected to support operations through \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. If sold off piecemeal, the integrated capability is lost.\u003c\/p\u003e\n\u003cp\u003eThe scale and certification of the manufacturing assets prior to the strategic review and subsequent liquidation are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFacility Location\u003c\/th\u003e\n\u003cth\u003eStatus\/Certification\u003c\/th\u003e\n\u003cth\u003ePeak Annual Capacity (cNeT Doses)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStevenage, UK (Catapult)\u003c\/td\u003e\n\u003ctd\u003eGMP Certified (MHRA Licensed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e200\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKing of Prussia, PA (CBM)\u003c\/td\u003e\n\u003ctd\u003ePartnership for Clinical Manufacturing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e150–200\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Additional Capacity\u003c\/td\u003e\n\u003ctd\u003eGlobal Footprint Expansion (as of April 2022)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e600\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe UK facility at the Cell \u0026amp; Gene Therapy Catapult received a manufacturing license from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This facility was part of an expansion of the CGT Catapult manufacturing centre which doubled its capacity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Stevenage, UK facility was GMP certified to produce clinical-grade doses of cNeT.\u003c\/li\u003e\n\u003cli\u003eThe US GMP manufacturing facility operated by CBM in King of Prussia, Pennsylvania, had an initial annual capacity of \u003cstrong\u003e150–200\u003c\/strong\u003e doses at peak production.\u003c\/li\u003e\n\u003cli\u003eThe total additional peak annual capacity announced in April 2022 was up to \u003cstrong\u003e600\u003c\/strong\u003e doses of cNeT.\u003c\/li\u003e\n\u003cli\u003eOne specific project related to the CGT Catapult manufacturing centre received \u003cstrong\u003e£3.36m\u003c\/strong\u003e of funding from the England European Regional Development Fund.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 8. Experienced Scientific and Clinical Leadership\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team possessed deep, multi-disciplinary knowledge in immuno-oncology, cell therapy, and genomics, which is rare in one group.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Finding leaders with this specific blend of expertise is tough.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. You can hire individuals, but recreating the team cohesion and shared history is nearly impossible.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Most key personnel likely departed following the strategic review and liquidation announcement in March 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The expertise walked out the door when the company dissolved its operating structure.\u003c\/p\u003e\n\u003cp\u003eThe scientific and clinical depth was evidenced by the composition of the Scientific Advisory Board (SAB) and senior management, which supported an R\u0026amp;D expense base of \u003cstrong\u003e$16.4 million\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eChief Scientific Officer, Sergio Quezada, stepped down effective \u003cstrong\u003eFebruary 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAll directors, including CEO Iraj Ali, resigned on \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e, upon shareholder approval of the Members' Voluntary Liquidation.\u003c\/li\u003e\n\u003cli\u003eThe company had \u003cstrong\u003e42,585,094\u003c\/strong\u003e ordinary shares outstanding as of \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents were reported at \u003cstrong\u003e$86.1 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company planned a 'further reduction in employee headcount' following the asset sale for \u003cstrong\u003e$12M\u003c\/strong\u003e in December 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRole\/Affiliation\u003c\/th\u003e\n\u003cth\u003eIndividual (Example)\u003c\/th\u003e\n\u003cth\u003eStated Expertise Area(s)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAB Member (Appointed 2020)\u003c\/td\u003e\n\u003ctd\u003eDr Elizabeth M. Jaffee\u003c\/td\u003e\n\u003ctd\u003eCancer Immunology, Pancreatic Cancer, AACR President\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAB Member (Appointed 2020)\u003c\/td\u003e\n\u003ctd\u003eDr Scott Antonia\u003c\/td\u003e\n\u003ctd\u003eThoracic Oncology, Immunotherapeutic Strategies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAB Member (Appointed 2022)\u003c\/td\u003e\n\u003ctd\u003eDr Cassian Yee, MD\u003c\/td\u003e\n\u003ctd\u003eMelanoma Medical Oncology, Adoptive Cellular Therapy Pioneer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSVP of Immunology and Process Development\u003c\/td\u003e\n\u003ctd\u003eDr Katy Newton\u003c\/td\u003e\n\u003ctd\u003eT cell and Dendritic cell Immunology, GMP production of autologous T cell therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAchilles Therapeutics plc (ACHL) - VRIO Analysis: 9. Residual Cash Reserves (Last Reported Runway)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The \u003cstrong\u003e$95.1 million\u003c\/strong\u003e in cash and equivalents reported as of June 30, 2024, provided the runway to fund operations through 2025 before the liquidation decision. The latest reported cash and equivalents balance was \u003cstrong\u003e$86.1 million\u003c\/strong\u003e as of September 30, 2024, supplemented by a cash R\u0026amp;D tax credit of \u003cstrong\u003e$12.8 million\u003c\/strong\u003e received in October 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Cash is fungible, but this amount was significant for a clinical-stage firm.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. It's a balance sheet item, not a unique skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This cash is now the primary asset being distributed to shareholders after creditors are paid, as per the March 2025 liquidation plan. The Joint Liquidators were appointed on March 20, 2025, following shareholder approval to commence a members' voluntary liquidation. Creditors were required to prove their debts before the deadline of \u003cstrong\u003eApril 22, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None. It is a financial resource being returned, not a source of future competitive edge.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Creditor Distribution Status and Subsequent Shareholder Distributions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Joint Liquidators stated the intention to make a first and final distribution to creditors, noting that \u003cstrong\u003eThe Companies are able to pay all its known creditors in full\u003c\/strong\u003e. The following table summarizes the distribution events subsequent to the creditor proof deadline:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Type\u003c\/th\u003e\n\u003cth\u003eRecord Date\/Declaration Date\u003c\/th\u003e\n\u003cth\u003eSecurity\u003c\/th\u003e\n\u003cth\u003eRate (Per Unit)\u003c\/th\u003e\n\u003cth\u003eCurrency\u003c\/th\u003e\n\u003cth\u003ePayment Start Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Interim Distribution (Creditor Payment Complete)\u003c\/td\u003e\n\u003ctd\u003eDeclared May 28, 2025\u003c\/td\u003e\n\u003ctd\u003eOrdinary Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e£1.100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGBP\u003c\/td\u003e\n\u003ctd\u003ePost-May 28, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Interim Distribution\u003c\/td\u003e\n\u003ctd\u003eConfirmed June 4, 2025\u003c\/td\u003e\n\u003ctd\u003eADS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.45868\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUSD\u003c\/td\u003e\n\u003ctd\u003eJune 11, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond and Final Distribution (Anticipated)\u003c\/td\u003e\n\u003ctd\u003eAnticipated\u003c\/td\u003e\n\u003ctd\u003eOrdinary Share\u003c\/td\u003e\n\u003ctd\u003eRemainder of £1.20 to £1.32 guidance\u003c\/td\u003e\n\u003ctd\u003eGBP\u003c\/td\u003e\n\u003ctd\u003eQ2 of 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe pre-liquidation guidance on total returns, before costs and fees, was:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e£1.20 to £1.32\u003c\/strong\u003e per Ordinary share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.50 to $1.66\u003c\/strong\u003e per ADS.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAs of the first interim distribution, \u003cstrong\u003e£1.10\u003c\/strong\u003e has been returned to Ordinary shareholders and \u003cstrong\u003e$1.45868\u003c\/strong\u003e is being returned to ADS holders. The Joint Liquidators anticipate declaring a second and final GBP distribution to Ordinary shareholders in \u003cstrong\u003eQ2 of 2026\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516103843989,"sku":"achl-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/achl-vrio-analysis.png?v=1740141324","url":"https:\/\/dcf-model.com\/pt\/products\/achl-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}